NEW YORK (GenomeWeb News) – Celera presented data at the annual American Association for Cancer Research meeting describing its mass spectrometry-based approach to identify and validate circulating protein biomarkers that detect non-small cell lung cancer. The company said that one outcome of the study was an immunoassay test for a panel of six biomarkers that detected lung cancer with 94 percent sensitivity and 93 percent specificity in a blinded analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.